|
1
|
Okuda K: Hepatocellular carcinoma. J
Hepatol. 32(Suppl 1): 225–237. 2000. View Article : Google Scholar
|
|
2
|
Rahbari NN, Mehrabi A, Mollberg NM, et al:
Hepatocellular carcinoma: current management and perspectives for
the future. Ann Surg. 253:453–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takara K, Sakaeda T and Okumura K: An
update on overcoming MDR1-mediated multidrug resistance in cancer
chemotherapy. Curr Pharm Des. 12:273–286. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhai BJ, Shao ZY, Zhao CL, Hu K and Wu F:
Development and characterization of multidrug resistant human
hepatocarcinoma cell line in nude mice. World J Gastroenterol.
12:6614–6619. 2006.PubMed/NCBI
|
|
5
|
Warmann S, Gohring G, Teichmann B,
Geerlings H, Pietsch T and Fuchs J: P-glycoprotein modulation
improves in vitro chemosensitivity in malignant pediatric liver
tumors. Anticancer Res. 23:4607–4611. 2003.PubMed/NCBI
|
|
6
|
Li B, Ye T, Zhao L, et al: Effects of
multidrug resistance, antisense RNA on the chemosensitivity of
hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int.
5:552–559. 2006.PubMed/NCBI
|
|
7
|
Merino V, Jimenez-Torres NV and
Merino-Sanjuan M: Relevance of multidrug resistance proteins on the
clinical efficacy of cancer therapy. Curr Drug Deliv. 1:203–212.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luqmani YA: Mechanisms of drug resistance
in cancer chemotherapy. Med Princ Pract. 14(Suppl 1): 35–48. 2005.
View Article : Google Scholar
|
|
9
|
Cardoso C, Mignon C, Hetet G, Grandchamps
B, Fontes M and Colleaux L: The human EZH2 gene: genomic
organisation and revised mapping in 7q35 within the critical region
for malignant myeloid disorders. Eur J Hum Genet. 8:174–180. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sewalt RG, van der Vlag J, Gunster MJ, et
al: Characterization of interactions between the mammalian
polycomb-group proteins Enx1/EZH2 and EED suggests the existence of
different mammalian polycomb-group protein complexes. Mol Cell
Biol. 18:3586–3595. 1998.
|
|
11
|
Koyanagi M, Baguet A, Martens J, Margueron
R, Jenuwein T and Bix M: EZH2 and histone 3 trimethyl lysine 27
associated with Il4 and Il13 gene silencing in Th1 cells. J Biol
Chem. 280:31470–31477. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao R, Wang L, Wang H, et al: Role of
histone H3 lysine 27 methylation in Polycomb-group silencing.
Science. 298:1039–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vire E, Brenner C, Deplus R, et al: The
Polycomb group protein EZH2 directly controls DNA methylation.
Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
De Haan G and Gerrits A: Epigenetic
control of hematopoietic stem cell aging the case of Ezh2. Ann N Y
Acad Sci. 1106:233–239. 2007.PubMed/NCBI
|
|
15
|
Caretti G, Di Padova M, Micales B, Lyons
GE and Sartorelli V: The Polycomb Ezh2 methyltransferase regulates
muscle gene expression and skeletal muscle differentiation. Genes
Dev. 18:2627–2638. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Varambally S, Dhanasekaran SM, Zhou M, et
al: The polycomb group protein EZH2 is involved in progression of
prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Visser HP, Gunster MJ, Kluin-Nelemans HC,
et al: The Polycomb group protein EZH2 is upregulated in
proliferating, cultured human mantle cell lymphoma. Br J Haematol.
112:950–958. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Steele JC, Torr EE, Noakes KL, et al: The
polycomb group proteins, BMI-1 and EZH2, are tumour-associated
antigens. Br J Cancer. 95:1202–1211. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sasaki M, Ikeda H, Itatsu K, et al: The
overexpression of polycomb group proteins Bmi1 and EZH2 is
associated with the progression and aggressive biological behavior
of hepatocellular carcinoma. Lab Invest. 88:873–882. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Y, Lin MC, Yao H, et al:
Lentivirus-mediated RNA interference targeting enhancer of zeste
homolog 2 inhibits hepatocellular carcinoma growth through
down-regulation of stathmin. Hepatology. 46:200–208. 2007.
View Article : Google Scholar
|
|
21
|
Hu S, Yu L, Li Z, et al: Overexpression of
EZH2 contributes to acquired cisplatin resistance in ovarian cancer
cells in vitro and in vivo. Cancer Biol Ther. 10:788–795. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ougolkov AV, Bilim VN and Billadeau DD:
Regulation of pancreatic tumor cell proliferation and
chemoresistance by the histone methyltransferase enhancer of zeste
homologue 2. Clin Cancer Res. 14:6790–6796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Simon JA and Lange CA: Roles of the EZH2
histone methyltransferase in cancer epigenetics. Mutat Res.
647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stewart ZA, Westfall MD and Pietenpol JA:
Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol
Sci. 24:139–145. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sudo T, Utsunomiya T, Mimori K, et al:
Clinicopathological significance of EZH2 mRNA expression in
patients with hepatocellular carcinoma. Br J Cancer. 92:1754–1758.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai MY, Tong ZT, Zheng F, et al: EZH2
protein: a promising immunomarker for the detection of
hepatocellular carcinomas in liver needle biopsies. Gut.
60:967–976. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grubach L, Juhl-Christensen C, Rethmeier
A, et al: Gene expression profiling of Polycomb, Hox and Meis genes
in patients with acute myeloid leukaemia. Eur J Haematol.
81:112–122. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Effendi K, Mori T, Komuta M, Masugi Y, Du
W and Sakamoto M: Bmi-1 gene is upregulated in early-stage
hepatocellular carcinoma and correlates with ATP-binding cassette
transporter B1 expression. Cancer Sci. 101:666–672. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
van Kemenade FJ, Raaphorst FM, Blokzijl T,
et al: Coexpression of BMI-1 and EZH2 polycomb-group proteins is
associated with cycling cells and degree of malignancy in B-cell
non-Hodgkin lymphoma. Blood. 97:3896–3901. 2001.PubMed/NCBI
|
|
30
|
Tan J, Yang X, Zhuang L, et al:
Pharmacologic disruption of Polycomb-repressive complex 2-mediated
gene repression selectively induces apoptosis in cancer cells.
Genes Dev. 21:1050–1063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY
and Yu Q: Polycomb protein EZH2 regulates E2F1-dependent apoptosis
through epigenetically modulating Bim expression. Cell Death
Differ. 17:801–810. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fussbroich B, Wagener N, Macher-Goeppinger
S, et al: EZH2 depletion blocks the proliferation of colon cancer
cells. PLoS One. 6:e216512011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hannon GJ: RNA interference. Nature.
418:244–251. 2002. View
Article : Google Scholar : PubMed/NCBI
|
